Humanigen Inc

Humanigen inks licensing agreement with the University of Zurich to strengthen its treatment of graft-versus-host disease in leukemia patients

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based company has a new tool in its box to prevent graft-versus-host disease when treating patients with leukemia and other blood cancers.

Durrant says Humanigen has received an exclusive licensing agreement from the University of Zurich in Switzerland to utilize its GM-CSF protein neutralization technology, shown to mitigate graft-versus-host without stifling the positive effects of leukemia treatment.

Quick facts: Humanigen Inc

Price: $1.10

Market: OTCQB
Market Cap: $124.05 m

More on this story


Redx Pharma gets green light to increase dose in lead cancer drug trial

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug. It comes after the firm successfully navigated the first part of its early-stage trial for RXC004. The asset's part...

2 days, 3 hours ago

2 min read